Patient-Derived Pancreatic Organoids Uncover CFTR Dysfunction as Therapeutic Target in Chronic Pancreatitis
核心洞察
Salk Institute (搜索) researchers developed a patient-derived pancreatic organoid platform generating 37 organoid lines from chronic pancreatitis (搜索) patients with diverse etiologies.
Approximately half of the organoids exhibited dysfunctional CFTR (搜索) protein, and this dysfunction was not limited to patients with inherited CFTR mutations.
Clinically available CFTR modulator (搜索) therapies successfully stabilized or restored CFTR (搜索) function and reduced inflammatory signaling in responsive organoids.
Chronic pancreatitis (搜索), a progressive inflammatory condition affecting approximately three million people worldwide, has long presented a formidable treatment challenge due to its diverse molecular underpinnings and the absence of disease-modifying therapies. Now, scientists at the Salk Institute (搜索) have developed a patient-derived organoid platform that not only illuminates the molecular mechanisms driving the disease but also identifies existing drugs that may offer therapeutic benefit.
In a study published in Cell Stem Cell on June 30, 2026, researchers led by senior author Dannielle Engle, PhD, assistant professor and Helen McLoraine Developmental Chair at Salk, generated 37 pancreatic organoid lines from patients who developed chronic pancreatitis (搜索) spontaneously, from genetic factors, or from other causes including alcohol-related disease.
A Platform Built on Patient Biology
Each organoid was created from donor pancreas tissues and validated to match the original patient tissue, preserving key molecules, proteins, and inflammatory factors. Unlike traditional two-dimensional cell cultures or animal models, these three-dimensional miniature organs better replicate the complex biology of human pancreatic ductal cells.
"By growing organoids directly from patients, we preserve key features of ductal cells and ask which disease mechanisms are active in each individual patient," said first author Victoria Osorio-Vasquez, PhD, a postdoctoral researcher in Engle's lab.
The team surveyed molecular signatures across all 37 organoid lines and identified three distinct subtypes of chronic pancreatitis (搜索). This biology-based stratification represents a potential paradigm shift from current treatment strategies that base care primarily on the cause of disease onset.
CFTR (搜索) Dysfunction Emerges as a Central Target
A striking finding emerged when the researchers discovered that approximately half of the organoids exhibited dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR (搜索)) protein. Notably, CFTR dysfunction was not confined to patients with inherited CFTR mutations.
"And CFTR (搜索) dysfunction was not limited to patients with inherited CFTR mutations, suggesting that functional testing may identify therapeutic opportunities that would be missed by genetic testing alone," Osorio-Vasquez noted.
This observation carries significant clinical implications. A range of CFTR modulator (搜索) therapies already exists, originally developed for patients with cystic fibrosis. The Salk team tested these clinically available modulators on the responsive organoids and found they could stabilize or restore CFTR (搜索) function while reducing inflammatory signaling.
"Though patients can have the same clinical diagnosis of chronic pancreatitis (搜索), they can have very different underlying molecular drivers of that disease, which makes treatment especially difficult," said Engle. "Our work breaks down a major barrier in the field by establishing an experimental model that preserves patient-specific disease biology and can be used to develop tailored therapies."
Beyond CFTR (搜索): Broader Implications
The platform also revealed rare alterations to genes coding for the proteins KRAS (搜索) and TP53 (搜索) in some chronic pancreatitis (搜索) organoids. These findings support future use of the system to study disease evolution, pancreatic cancer risk, and biomarker discovery at the interface of chronic inflammation and pancreatic cancer.
"These organoids gave us a way to study chronic pancreatitis (搜索) pathogenesis in human cells for the first time," Engle said. "Our platform enables a more personalized way of studying and eventually treating chronic pancreatitis, while also blazing the trail for other organoid-based platforms in other inflammatory disease contexts."
The successful demonstration that CFTR (搜索) modulators can reduce inflammatory signaling in responsive pancreas organoids paves the way for follow-up clinical trials, offering hope that the first disease-modifying treatments for chronic pancreatitis (搜索) may emerge from this organoid-driven precision medicine approach.